rAAV vector-mediated gene therapy for experimental ischemic stroke.

Area of Science:

• Neuroscience
• Molecular Biology
• Gene Therapy

Background:

• Recombinant adeno-associated virus (rAAV) is the leading viral vector for gene therapy, with ongoing Phase I clinical trials.
• rAAV vectors have advanced significantly in gene delivery and transgene expression for therapeutic applications.

Purpose of the Study:

• To review the fundamental biology and development of rAAV vectors.
• To summarize recent advancements in using rAAV vectors for ischemic stroke gene therapy in preclinical models.

Main Methods:

• Modification of rAAV capsid for improved gene delivery.
• Encapsidation of double-stranded rAAV genomes to enhance transgene expression.
• Delivery of therapeutic genes to rodent stroke models via various administration routes.

Main Results:

• Successful delivery of nine therapeutic genes across 12 studies in rat and mouse ischemic stroke models.
• Demonstrated efficient gene expression and significant therapeutic efficacy with favorable biological safety profiles.
• rAAV-mediated gene therapy effectively attenuated ischemic brain damage in animal experiments.

Conclusions:

• rAAV vectors are a safe and effective platform for gene therapy in ischemic stroke.
• rAAV holds substantial promise for future clinical translation in stroke patients.
• Continued research into rAAV vector development and application is crucial for advancing stroke treatment.